129 related articles for article (PubMed ID: 10168532)
1. Aerosolized amiloride: dose effect on nasal bioelectric properties, pharmacokinetics, and effect on sputum expectoration in patients with cystic fibrosis.
Hofmann T; Senier I; Bittner P; Hüls G; Schwandt HJ; Lindemann H
J Aerosol Med; 1997; 10(2):147-58. PubMed ID: 10168532
[TBL] [Abstract][Full Text] [Related]
2. Effects of topically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis.
Hofmann T; Stutts MJ; Ziersch A; Rückes C; Weber WM; Knowles MR; Lindemann H; Boucher RC
Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1844-9. PubMed ID: 9620916
[TBL] [Abstract][Full Text] [Related]
3. The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis.
Rodgers HC; Knox AJ
Eur Respir J; 1999 Sep; 14(3):693-6. PubMed ID: 10543294
[TBL] [Abstract][Full Text] [Related]
4. [Pilot study of amiloride inhalation in children with cystic fibrosis].
Riedler J; Huttegger I
Klin Padiatr; 1992; 204(3):158-62. PubMed ID: 1614182
[TBL] [Abstract][Full Text] [Related]
5. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy.
App EM; King M; Helfesrieder R; Köhler D; Matthys H
Am Rev Respir Dis; 1990 Mar; 141(3):605-12. PubMed ID: 2310093
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis.
Knowles MR; Church NL; Waltner WE; Yankaskas JR; Gilligan P; King M; Edwards LJ; Helms RW; Boucher RC
N Engl J Med; 1990 Apr; 322(17):1189-94. PubMed ID: 2157983
[TBL] [Abstract][Full Text] [Related]
7. [Elimination of secretions in CF patients under amiloride inhalation].
Lindemann H; Becker T; Bittner P; Boldt A; Hofmann T; Schwandt HJ
Pneumologie; 1990 Oct; 44(10):1148-50. PubMed ID: 2281055
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis.
Jones KM; Liao E; Hohneker K; Turpin S; Henry MM; Selinger K; Hsyu PH; Boucher RC; Knowles MR; Dukes GE
Pharmacotherapy; 1997; 17(2):263-70. PubMed ID: 9085317
[TBL] [Abstract][Full Text] [Related]
9. Amiloride inhalation therapy in cystic fibrosis. Influence on ion content, hydration, and rheology of sputum.
Tomkiewicz RP; App EM; Zayas JG; Ramirez O; Church N; Boucher RC; Knowles MR; King M
Am Rev Respir Dis; 1993 Oct; 148(4 Pt 1):1002-7. PubMed ID: 8214916
[TBL] [Abstract][Full Text] [Related]
10. Aerosolized amiloride as treatment of cystic fibrosis lung disease: a pilot study.
Knowles MR; Church NL; Waltner WE; Yankaskas JR; Gilligan P; King M; Edwards LJ; Helms RW; Boucher RC
Adv Exp Med Biol; 1991; 290():119-28; discussion 129-32. PubMed ID: 1950741
[No Abstract] [Full Text] [Related]
11. Amiloride-insensitive nasal potential difference varies with the menstrual cycle in cystic fibrosis.
Sweezey NB; Smith D; Corey M; Ellis L; Carpenter S; Tullis DE; Durie P; O'Brodovich HM
Pediatr Pulmonol; 2007 Jun; 42(6):519-24. PubMed ID: 17469152
[TBL] [Abstract][Full Text] [Related]
12. Modification of nasal membrane potential difference with inhaled amiloride and loperamide in the cystic fibrosis (CF) mouse.
Ghosal S; Taylor CJ; McGaw J
Thorax; 1996 Dec; 51(12):1229-32. PubMed ID: 8994520
[TBL] [Abstract][Full Text] [Related]
13. [Amiloride inhalation therapy in mucoviscidosis].
Lindemann H
Monatsschr Kinderheilkd; 1993 May; 141(5):392-4. PubMed ID: 8326957
[TBL] [Abstract][Full Text] [Related]
14. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis.
App EM; Baran D; Dab I; Malfroot A; Coffiner M; Vanderbist F; King M
Eur Respir J; 2002 Feb; 19(2):294-302. PubMed ID: 11866009
[TBL] [Abstract][Full Text] [Related]
15. Effect of uridine 5'-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis.
Bennett WD; Olivier KN; Zeman KL; Hohneker KW; Boucher RC; Knowles MR
Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1796-801. PubMed ID: 8665037
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of intranasal Moli1901 for cystic fibrosis.
Zeitlin PL; Boyle MP; Guggino WB; Molina L
Chest; 2004 Jan; 125(1):143-9. PubMed ID: 14718433
[TBL] [Abstract][Full Text] [Related]
17. Effect of amiloride on potential difference across rectal mucosa in cystic fibrosis patients.
Patton CJ; Jenkins MQ; Briggman JV; Spicer SS
Pediatr Res; 1982 Dec; 16(12):1035-6. PubMed ID: 6296753
[TBL] [Abstract][Full Text] [Related]
18. Measurement of airway ion transport assists the diagnosis of cystic fibrosis.
Middleton PG; House HH
Pediatr Pulmonol; 2010 Aug; 45(8):789-95. PubMed ID: 20597077
[TBL] [Abstract][Full Text] [Related]
19. Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium.
Middleton PG; Geddes DM; Alton EW
Eur Respir J; 1994 Nov; 7(11):2050-6. PubMed ID: 7875281
[TBL] [Abstract][Full Text] [Related]
20. No added benefit from nebulized amiloride in patients with cystic fibrosis.
Graham A; Hasani A; Alton EW; Martin GP; Marriott C; Hodson ME; Clarke SW; Geddes DM
Eur Respir J; 1993 Oct; 6(9):1243-8. PubMed ID: 8287938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
